Avid Bioservices Inc (CDMO)

[entdoc]

weekly PPHM recap. The bottom arrived with a ten cent bounce which almost tranquelized shell-shocked PPHM retail stockholders fearing the worst. However, moments of light peeked through, such as when one poster wrote that PPHM's wholly owned subsidiary, Avid, an FDA certified manufacturer of the most brill and complex monoclonal antibodies, alone is worth the float.
Until the,uh,boardroom bulls gain enough maneuvering room to divvy up the gazillions, retail stockholders pray they're hangin' onto the right coattails and have enough voice to shout what they thimpk about ten cent turn-arounds. Another idea a poster here had, that this might be a "quiet time,"--can't remember his penname, the one who posts a photo of himself: happy-looking; in cover-alls; and smoking a corn cob pipe. He postulated the company silence might be mandated by a soon-to-be-announced take-over announcement.
Retail stockholders are so shell-shocked at this point most would agree with a low multiple to par buy-out, as if it would be a blessing. A takeover at this point makes sense. A charade usually ends when everyone is in on it, and the value of PPHM intellectual properties remains inestimable. Roche/DNA are stymied, resorting to a conjugate of Herceptin now. Be real. Herceptin, Avastin, ERbitox,and that ilk are old, and now ineffective warriors. Let them retire with dignity. I agree with those posters here who decry the inhumane delays...no matter what spoke they are in the wheel. Roche does not appear to be the winner here. BMY just bought a fully humanized EGF MAB to replace erbitux. Got it right. It must be Merck. International clout. Getting PPHM would be the coup of the century.